Commencement Of A Phase II Clinical Trial Of SG2000 In Ovarian Cancer

Links shared publicly online about this topic.

869
total visits

Commencement Of A Phase II Clinical Trial Of SG2000 In Ovarian Cancer

Spirogen Limited (the Company) and Celtic Therapeutics Holdings LP (Celtic Therapeutics) announced the commencement of a Phase II clinical trial of SG2000 in ovarian cancer. The trial is bein

View full resource at medicalnewstoday.com

Tags: Cancer, Ovarian Cancer, Clinical Trial, Women's Health

Most Recently Shared on September 16, 2010 at 5:40 pm By:

Ovarian Cancer OW

Commencement Of A Phase II Clinical Trial Of SG2000 In Ovarian Cancer: Spirogen Limited (the "Company") and Celtic... http://mnt.to/f/3JQh

2 years ago...

Retweet

Favorite

Also Shared By:

MNT Ovarian Cancer

MNT Pharma News

MNT Clinical Trials

Endocyte receives payment for the advancement of epothilone-folate anti-cancer agent

news-medical.net — “Endocyte, Inc., a cancer drug discovery and development company, today announced it has received a milestone payment from Bristol-Myers Squibb Company (NYSE: BMY). This payment was triggered by the commencement of a Phase II clinical trial for an epothilone-folate anti-cancer agent identified through the collaboration between Endocyte and Bristol-Myers Squibb scientists.” View full resource at news-medical.net